Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus VulgarisDario Didona, Michael Hertl, Katja Kühn et al.|Journal of Investigative Dermatology|2023Cited by 14
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Michael Hertl, Christoph Hudemann et al.|British Journal of Dermatology|2025Cited by 5
Pemphigus: a critical analysis on clinical subtypes, pathogenesis, diagnostics and established novel therapeuticsRüdiger Eming, Michael Hertl, Christine L. Zimmer|Italian Journal of Dermatology and Venereology|2021Cited by 1
Quality-controlled characterization of a monoclonal antibody specific to an EC5-domain of human desmoglein 3 for pemphigus researchRüdiger Eming, Christoph Hudemann, Shafaq Riaz et al.|Frontiers in Immunology|2024Cited by 1